Shortage of Ketorolac Tromethamine Injection in the US
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA has reported a current shortage of Ketorolac Tromethamine Injection, affecting various manufacturers and presentations, with some limited availability.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Ketorolac Tromethamine) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
The generic drug Ketorolac Tromethamine Injection, also known by the brand name KETOROLAC TROMETHAMINE, is currently in shortage. It is an injection in the therapeutic category of Analgesia/Addiction. The shortage was first posted on March 26, 2018, and last updated on March 27, 2026.
Which Manufacturers Are Affected
- Hospira, Inc., a Pfizer Company: Limited Availability for Ketorolac Tromethamine Injection, 30 mg/1 mL (NDC 0409-3795-01) and 60 mg/2 mL (NDC 0409-3796-01), with limited supply available and next delivery estimated for June 2027. Contact: 844-646-4398. Also, Unavailable for 15 mg/1 mL (NDC 0409-3793-01), with next delivery and estimated recovery in June 2027.
- Baxter Healthcare: Unavailable for Ketorolac Tromethamine Injection, 30 mg/1 mL (NDC 0338-0072-25), with estimated recovery TBD. Contact: 888-229-0001. However, Available for 15 mg/1 mL (NDC 0338-0069-10).
- Fresenius Kabi USA, LLC: Unavailable for several presentations, including 15 mg/1 mL (NDC 76045-107-10 and NDC 63323-161-01), 30 mg/1 mL (NDC 63323-162-01 and NDC 76045-104-10 and NDC 63323-162-02), and 60 mg/2 mL (NDC 76045-105-20). Expected recovery: TBD for most, with next release April 2026 for some. Contact: 888-386-1300.
Why There's a Shortage
The reason for the shortage is listed as 'Other,' and no specific details were provided.
What Patients Should Do
Patients who depend on this medication should talk to their pharmacist or healthcare provider about the current availability. They can also contact the relevant manufacturers for more information. Please remember that patients should always consult their healthcare provider for any advice regarding their treatment and not make changes without professional guidance.
Source
This information is from the FDA Drug Shortage Database, initially posted on March 26, 2018, and last updated on March 27, 2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.